Physician profile
Pooja Malik
NPI 1568578599
$3,670.85
in general payments reported to CMS, 2019-2025
13 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $323 · 2021: $433 · 2022: $47.54 · 2023: $451 · 2024: $798 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967 · Travel and Lodging: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.84 |
| Travel and Lodging | $156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,061.06 | 2019-2025 | Xeomin |
| Revance Therapeutics, INC. | $773.93 | 2024-2025 | Daxxify |
| Abbvie INC. | $310.97 | 2021-2025 | |
| Galderma Laboratories, L.P. | $212.12 | 2020-2025 | |
| Allergan, INC. | $141.79 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $27.36 | 2024 | |
| Mannkind Corporation | $27.29 | 2019 | |
| Glaxosmithkline, LLC. | $26.53 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $26.15 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.39 | 2022 | |
| Amarin Pharma, INC. | $14.29 | 2019 | |
| Horizon Therapeutics Plc | $14.06 | 2023 | Krystexxa |
| Lilly USA, LLC | $13.91 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.